Abstract 1162P
Background
Tumor acidity negatively regulates tumor-specific effector T cells in the tumor microenvironment. Conflicting results emerged on the impact of PPI on the efficacy of ICB.
Methods
A retrospective analysis was conducted on patients (pts) with metastatic melanoma treated with ICB between 2019 and 2020 at the Christie NHS Foundation Trust. Data on demographics, sites of disease, performance status (PS), comorbidities, types of therapy, progression-free (PFS), and overall survival (OS) were collected. Statistical analyses were performed with univariable and multivariable Cox regression models. The aim was to define the association between PPI exposure (defined as 30 days before or after the initiation of ICB and for at least 21 days concomitant with ICB) and PFS, and OS.
Results
Data was collected on 189 pts with a median age of 60 years; 57.14% were male, 88% had ECOG PS 0/1, 17% were BRAF mutant, 28% had elevated serum LDH, and 28.5% had brain metastases. 162 (86%) pts received ICB as their first line of treatment for advanced disease. The majority of pts (92%) received ipilimumab and nivolumab, and 8% received pembrolizumab. 83 (44%) of pts were identified as PPI users with a median duration of PPI use concomitantly with ICB of 365 days (range 21-1976 days). PPI use was significantly associated with longer median PFS (not reached vs. 7.3 months, Hazard ratio (HR):0.53, 95%CI:0.35-0.79, p=0.002) and longer median OS (not reached vs. 17.2 months, HR:0.47, 95%CI:0.30-0.73, p=0.001). In a multivariable regression analysis accounting for age, gender, PS, Charlson comorbidity score, BRAF status, elevated LDH, brain and liver metastases, and line of treatment, the favorable impact of PPI use on PFS (HR:0.53, 95%CI:0.35-0.81, p=0.003) and OS (HR: 0.43, 95%CI:0.27-0.69, p<0.0001) was maintained.
Conclusions
Exposure to PPI for more than 21 days at the initiation of ICB mediates better clinical outcomes. Our findings suggest that the duration and timing of PPI use should be considered when investigating the impact on ICB outcomes. Prospective studies are required to test the priming effect of PPI on tumors with acidic microenvironments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Christie NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1100P - Open-label non-randomized phase IB study to characterize the safety, tolerability and recommended dose of tinostamustin in combination with nivolumab in patients with advanced melanoma (ENIGMA)
Presenter: Markus Joerger
Session: Poster session 13
1101P - The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Presenter: Jordi Rodon
Session: Poster session 13
1102P - Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
Presenter: Peter Mohr
Session: Poster session 13
1103P - Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Presenter: Georgina Long
Session: Poster session 13
1104P - Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Presenter: Michael Weichenthal
Session: Poster session 13
1105P - First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
Presenter: Katarzyna Kozak
Session: Poster session 13
1106P - Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
Presenter: Ines Pires da Silva
Session: Poster session 13
1107P - BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
Presenter: Alexander Shoushtari
Session: Poster session 13
1108P - Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete response or toxicities
Presenter: Nur Sakinah Zulkifli
Session: Poster session 13